These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21737263)

  • 1. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.
    Kinzel O; Alfieri A; Altamura S; Brunetti M; Bufali S; Colaceci F; Ferrigno F; Filocamo G; Fonsi M; Gallinari P; Malancona S; Hernando JI; Monteagudo E; Orsale MV; Palumbi MC; Pucci V; Rowley M; Sasso R; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4429-35. PubMed ID: 21737263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1.
    Malancona S; Altamura S; Filocamo G; Kinzel O; Hernando JI; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4422-8. PubMed ID: 21737272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.
    Ontoria JM; Bufi LL; Torrisi C; Bresciani A; Giomini C; Rowley M; Serafini S; Bin H; Hao W; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5274-82. PubMed ID: 21803580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.
    Jin M; Kleinberg A; Cooke A; Gokhale PC; Foreman K; Dong H; Siu KW; Bittner MA; Mulvihill KM; Yao Y; Landfair D; O'Connor M; Mak G; Pachter JA; Wild R; Rosenfeld-Franklin M; Ji Q; Mulvihill MJ
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1176-80. PubMed ID: 21251824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
    Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
    J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
    Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
    Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors.
    Queiroz KC; Spek CA; Peppelenbosch MP
    Drug Resist Updat; 2012 Aug; 15(4):211-22. PubMed ID: 22910179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
    Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
    Bisht S; Brossart P; Maitra A; Feldmann G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
    Tremblay MR; Nesler M; Weatherhead R; Castro AC
    Expert Opin Ther Pat; 2009 Aug; 19(8):1039-56. PubMed ID: 19505195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imidazo-pyrazine derivatives as potent CXCR3 antagonists.
    Du X; Gustin DJ; Chen X; Duquette J; McGee LR; Wang Z; Ebsworth K; Henne K; Lemon B; Ma J; Miao S; Sabalan E; Sullivan TJ; Tonn G; Collins TL; Medina JC
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5200-4. PubMed ID: 19631529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.
    Scales SJ; de Sauvage FJ
    Trends Pharmacol Sci; 2009 Jun; 30(6):303-12. PubMed ID: 19443052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
    Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
    Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog pathway inhibitors: a patent review (2009--present).
    Hadden MK
    Expert Opin Ther Pat; 2013 Mar; 23(3):345-61. PubMed ID: 23294277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Hedgehog Antagonists for Cancer Therapy.
    Khatra H; Bose C; Sinha S
    Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
    Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
    J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.
    Banerjee U; Hadden MK
    Expert Opin Drug Discov; 2014 Jul; 9(7):751-71. PubMed ID: 24850423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
    Wang C; Zhu M; Lu X; Wang H; Zhao W; Zhang X; Dong X
    Bioorg Med Chem; 2018 Jul; 26(12):3308-3320. PubMed ID: 29739714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.